Discover and read the best of Twitter Threads about #GlobalOncology
Most recents (5)
Cancer vanishes from every patient’s body in drug trial “miraculously”; Shocked doctors’ say ‘First time in history’ financialexpress.com/healthcare/new…
What miracle are we talking about?
A drug called dostarlimab, an anti–PD-1 monoclonal antibody (immunotherapy), was given every 3 weeks for 6 months in patients with a subgroup of patients with rectal cancer (stage II or III, mismatch repair–deficient or MMR-deficient). (2/9)
A drug called dostarlimab, an anti–PD-1 monoclonal antibody (immunotherapy), was given every 3 weeks for 6 months in patients with a subgroup of patients with rectal cancer (stage II or III, mismatch repair–deficient or MMR-deficient). (2/9)
What is the buzz about?
Of the patients given the treatment, and evaluated, all of them had complete disappearance of tumor after 6 months of treatment. Now, this is remarkable, and is the reason why there is a lot of excitement in the oncology community about the results (3/9)
Of the patients given the treatment, and evaluated, all of them had complete disappearance of tumor after 6 months of treatment. Now, this is remarkable, and is the reason why there is a lot of excitement in the oncology community about the results (3/9)
Hi, #ASCO21 world. As you get bombarded with news of the remarkable new therapies, I request you to kindly read these 3 papers to put things into context.
1. Trials that are flawed in design, analysis, and interpretation can give false signal of benefit- esmoopen.com/article/S2059-… 1
1. Trials that are flawed in design, analysis, and interpretation can give false signal of benefit- esmoopen.com/article/S2059-… 1
2. Drugs that are claimed to be "well-tolerated" or having a "favourable" or "Acceptable" toxicity profiles are usually not so. These are almost misnomers. Look into the safety data yourself. bmj.com/content/363/bm… 2
Patients in LMICs are still dying not because they didn't have access to the newest checkpoint inhibitor but because they didn't have access to surgery/radiation/pathology/chemo and other basic services. #cancergroundshot #globaloncology thelancet.com/journals/lanon…
It was my pleasure sharing some thoughts on communication skills in oncology with the participants of @ecancer #Kolkata21 meeting today morning. The video is already available to watch for those interested: ecancer.org/en/video/9670-…
With special thanks to @ChernyNathan @scottrberry and @ramsedhom for providing me advice/thoughts/slides to make this talk possible. I myself learned a lot in this process.
Many thanks to @HealthCommunic2 for organizing the event. Missed meeting all dear friends and colleagues in person, hopefully next year we can.
Published just now in @ASCO_pubs JCO Global Oncology. The FIRST report of a population-based cancer registry from Nepal. It felt very meaningful to contribute to this #cancergroundshot project. ascopubs.org/doi/full/10.12… #globaloncology
For the first time, we now have official data on the commonest cancers in Kathmandu by incidence and mortality in different subgroups of population. ascopubs.org/doi/full/10.12…
The population-based cancer registry has only just started in Nepal, and there are plenty of room for improvement. But I hope this provides the foundation for stronger work in the future. ascopubs.org/doi/full/10.12…
This thread is going to be a collection of all my #globaloncology papers, primarily for my own reference to bookmark for quick access but also, just in case, it is helpful for any colleague with an interest in global oncology. 1/
This was my first publication ever. A correspondence to @TheLancetOncol in 2014 about cancer care and research in Nepal with @Poudyalbishesh : thelancet.com/journals/lanon…
This is probably one of the most important papers we’ve ever published. This paper in British Journal of Hematology highlights the story of how Bone Marrow Transplant services started in Nepal under @Poudyalbishesh ‘s initiative. onlinelibrary.wiley.com/doi/full/10.11…
